Stifel Initiates Coverage On MBX Biosciences with Buy Rating, Announces Price Target of $40

Benzinga · 10/08 11:50
Stifel analyst Annabel Samimy initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Buy rating and announces Price Target of $40.